- Leap Therapeutics Inc ASCO GI 2024 DeFianCe Study Webcast TranscriptJan 23, 2024
- Leap Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Leap Therapeutics Inc at Robert W Baird Global Healthcare Conference TranscriptSep 13, 2023
- Leap Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2023
- Leap Therapeutics Inc Acquires Flame Biosciences TranscriptJan 17, 2023
- Leap Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Leap Therapeutics Inc - R&D Day TranscriptJul 12, 2022
- Leap Therapeutics Inc ASCO GI 2022 DisTinGuish Study Conference Call TranscriptJan 21, 2022
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Leap Therapeutics Inc ESMO 2021 DisTinGuish Study Conference Call TranscriptSep 17, 2021
- Leap Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Leap Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Leap Therapeutics Inc DKN-01 Clinical Data Conference Call TranscriptMar 22, 2021
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptApr 23, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptAug 06, 2019
Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Thank you. It's a pleasure to start the new year here at the 40th Annual JPMorgan Healthcare Conference. I'm Doug Onsi, the President and CEO of Leap Therapeutics, and I'm proud to be able to give you an update on the clinical development of DKN-01 and our plans for 2022. Then we'll head into the virtual breakout room for questions and answers. While I'll be joined by Cyndi Sirard, our Chief Medical Officer; and Jay Baum, our Vice President and Head of Translational Research. My presentation will include forward-looking statements.
Please advance to Slide 3. LEAP Therapeutics is an oncology drug development company focused on developing our DKN-01 monoclonal antibody. DKN-01 targets DKK1, a protein produced by cancer cells that modulates important cell signaling pathways and playing a key role in maintaining an immunosuppressive tumor microenvironment. DKN-01 has demonstrated single-agent activity in 3 tumor types: esophagogastric cancer, non-small cell lung cancer and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)